head title

"The most active body healing peptide available!"

Elite soldiers and athletes use it to recover and heal wounds TWICE faster! link to buy
But it's also used for ulcers, burns, sprains, etc...
it simply signals the body to accelerate any healing process!

Pro-Healer or BPC 157 is an external and internal healing protein, oral and topical, applied to external sores, cuts and abrasions, will increase healing time dramatically.
Studies have shown that BPC157, taken orally, 1mg daily, can help to reverse ulcer damage, reduce inflammation through out the digestive tract and heal liver from alcohol and other damage among other things.
The trials and potential uses for this protein are endless and continuing!

Testimonies BPC 157 from Biotrends clients

Pro-Healer-biotrends-bpc157-101I personally would say that a key note to taking the BPC is about its anti-inflammatory capabilities through out the body.

Yes, it lets the body heal fast, it takes care of IBS’s

(Irritable Bowel Syndrome)

and more, but, concerning specifically anti-ageing, it’s its ability to reduce, even eliminate, swelling through out the body.

You and I both know, from our research, that swelling is a major cause of ageing.

This product is also included in their anti-ageing flagship “Rejuvenate Super Set” available here, on which you can get -10% by subscribing at the convenient monthly autoship here.

Here are a few testimonies I received from people using the PRO-HEALER BPC157 manufactured by Biotrends HK. I usual I removed the family names:

1.    Jack T.:  73 years old, Tulsa Oklahoma
I have been suffering from sore joints, tendons and slow to healing for many years now.  A friend of mine recommended I try Pro-Healer BPC-157 and I just felt I needed to write to you and let you know how much I appreciate this product.

The swelling and pain in my joints and the soreness of my tendons has diminished to the point that I often forget I had the problem.  As an added, unexpected, benefit, my stomach no longer hurts in the morning. Maybe I had an ulcer I was not aware of?  I did read that it helps, even can cure ulcers in a few days.  Thank you again.


2.   Roberta B.:  48,  Alberta Canada

This Pro-Healer has been a life saver for me.  I have been diagnosed with Crohn’s Disease for many years now.  Quite often the pain is unbelievable.  I have had to have 3 resections of my intestines so far and I was truly afraid of my future.

Now with the Pro-Healer, I never have pain, all the bloating and swelling is gone.  My doctor is amazed at the change I have had.

The only time I have had a problem since was when I stopped taking it last summer while I was travelling but I started again when I returned home and all is fine again.  I wish you could do an auto-ship for me.


3.        Stephan C.:  52,  Belgium

I am a diabetic and suffer from ulcers on my feet.  I have already lost 1 toe due to this problem.

I am very happy with the Pro-Healer as it has healed my skin ulcers in a very short amount of time.

I mixed it up, just as it shows on the box, and I apply it to all my wounds daily.  At first I thought it would not work, I suppose my expectations were very high and I was wanting instant results.

After a couple of days, however, it was very clear that they were healing and healing quickly.

I have tried so many different things but have never had these kind of results.  I believe that because of Pro-Healer I can manage to keep from loosing any more toes.  I am very happy, thank you so much.


➡ You can see this product here

➡ And register at Biotrends, it’s free here

Impact of BPC 157 on healing of ileorectal anas

Predrag Sikiric discusses DDW 2014 Research Forum presentation 134: ‘The impact of the pentadecapeptide BPC 157 on the healing of ileorectal anastomosis in rats following the subtotal colectomy’ scheduled for Saturday, May 3, 2014

 

Comment published below this short video presentation:

MrPopular22 (December 2015)
I had a painful strong inflammation of my espohagus due to Hiatal hernia and the reflux coming from it for years. It was surgically repaired in 2008, but the pain got even worse after the surgery. I had inflamed esophagus, esophageal cramps which could go on for 2 days without a break and were extremly painful. I also had difficulty with swallowing besides that the hiatal hernia repair was NOT too narrow (Diagnosed: “esophageal hypomotility”), my mouth would feel sore every morning after wakeup due to the Reflux and many many other symptoms that were horrible.
Nothing would help, no PPI medication, no antacids, no home remedies, absolutely nothing and all this got worse and worse year after year.

Long story short: I found this peptide this year and started taking it due to my hopelessness for exactly one month (August – September) and it worked wonders. I can`t even believe what this has done in just 4 weeks. From September until now, i have not had one single cramp in my esophagus, my heartburn is COMPLETLY gone, i can sleep normally, i have no more constant pain and i can swallow without problems, i don`t need medication anymore, , i have no more taste of acid in the mouth every morning and my mouth has healed completly. And that effect stayed even after stopping this peptide for almost two months. This stuff is INCREDIBLE.

Now i`m afraid of possible long term effects of this substance, but for now, it gave me back my life.

 

Video link: https://www.youtube.com/watch?v=y0TYr3jW0rk

BPC157 counteracts brain damages and convulsions

The Department of Pharmacology and Pathology,

Medical Faculty University of Zagreb, Zagreb, Croatia published this paper in 2010

“HIGH HEPATOTOXIC DOSE OF PARACETAMOL PRODUCES GENERALIZED
CONVULSIONS AND BRAIN DAMAGE IN RATS. A COUNTERACTION WITH
THE STABLE GASTRIC PENTADECAPEPTIDE BPC 157 (PL 14736)”

 

To demonstrate possible BPC 157 therapy capability as a paracetamol antidote in early and advanced stage of paracetamol toxicity, BPC 157 was applied intraperitoneally or intragastrically (12, 13) (i) prophylactically, immediately after paracetamol or (ii) therapeutically, after 3 hours elapsed.

Presenting the generally known significance of paracetamol toxicity (1-3, 6, 11), this may reveal the role of BPC 157 (i.e., a free radical scavenger (17, 29)) against the early paracetamol lesions development, and even more importantly, when the original damaging process induced by an extreme paracetamol over-dose was highly advanced.

 

Discussion extracts:

“However, we shown that pentadecapeptide BPC 157, as an antiulcer peptide (12-15), may consistently counteract all paracetamol disturbances. This may also indicate that these disturbances are also interconnected throughout BPC 157 background. Moreover, considering the used paracetamol (5 g/kg i.p.)/BPC 157 (10 µg, 10 ng, 10 pg/kg i.p. or i.g., and effectiveness within µg-ng range) ratio (12, 13), it may be reasonably to assume that these therapy effects may indicate a likely role of BPC 157 in controlling, and then, counteracting one or more causative process(es).”

“What’s more, the premise that when given peripherally, BPC 157 may have a particular beneficial effect on CNS (i.e., markedly less damaged neurons in most severely injuried areas) is in accord with: its neuroprotective properties (22, 34), consistent antagonization of different central disturbances (16-23, 34),…”

“Also, BPC 157 was found to have anti-convulsive properties (16, 17, 21).

Also very recently, with the respect of K+-ATP channels in the substantia nigra as a predisposing factor for seizure development, BPC 157 inhibits K+ conductance in WT HEK293 cells (36).

Besides, after an induced traumatic brain injury in mice, BPC 157 regimens (corresponding to those used in the present study) demonstrated a marked attenuation of damage with an improved early outcome and a minimal postponed mortality throughout a 24 h post-injury period.

Ultimately, the traumatic lesions (subarachnoidal and intraventricular haemorrhage, brain laceration, haemorrhagic laceration) were less intense and consecutive brain edema had considerably improved (22).”

 

“In conclusion, we showed the progressive hepatic encephalopathy, accompanied by severe seizures with a very early onset, in paracetamol-rats (i.e., the full threatening circuit in paracetamol’s acute hepatic toxicity).

This was consistently counteracted by the stable gastric pentadecapeptide BPC 157, showing this peptide as an effective antidote therapy (i.e., given in µg- and ng-dose regimens in either stage of paracetamol intoxication).

Also, when given parenterally or per-orally (i.e., stable in human gastric juice for more than 24 h (12, 13)), in the same dose-regimens, BPC 157 protected against various agents or procedures that would otherwise have lead to severe liver lesions (29-31) or CNS disturbances (16-23).”

 

“Finally, BPC 157 counteracted a particular overdose toxicity that excided regular paracetamol regimens (i.e., 1, 2, 6, 11), at either of the assessed intervals (i.e., 25 min, 3 hours and 24 hours). On the other hand, the demonstration of paracetamol’s progressive hepatic encephalopathy with severe seizures at least partly overruled the general discordance of NSAIDs’ adverse effects and therapeutic application, paracetamol in particular as previously mentioned (1-10).

Also, the significance of this peptide’s therapeutic benefit against amplified and advanced paracetamol toxicity remains to be further postulated, particularly considering the extensive investigation of gastrointestinal peptides in gastrointestinal and liver physiology (38), physiological mediators in NSAIDs-induced impairment of gastric mucosal defense and adaptation (39), and brain-gut peptide regulation (40). However, very recent novel evidence suggested that just the stable gastric pentadecapeptide BPC 157 may have possible significance and implications for novel mediator of both Robert’s cytoprotection and adaptive cytoprotection (41), and thereby potential to counteract paracetamol and other NSAIDs (over)-toxicity.”

 

Source of the paper: http://www.jpp.krakow.pl/journal/archive/04_10/articles/15_article.html

 

Useful Cited References:

  • 12- Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol (Paris) 1993; 87: 313-327.
  • 13- Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology 2006; 14: 214-221.
  • 15- Sikiric P, Seiwerth, S, Grabarevic Z, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol 1997; 332: 23-33.
  • 16- Boban Blagaic A, Blagaic V, Mirt M, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol 2005; 512: 173-179.
  • 17- Sikiric P, Marovic A, Matoz W, et al. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson’s disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine. J Physiol (Paris) 1999; 93: 505-512.
  • 21- Blagaic AB, Blagaic V, Romic Z, Sikiric P. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. Eur J Pharmacol 2004; 499: 285-290.
  • 22- Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept 2010; 160: 26-32.
  • 23-  Boban Blagaic A, Turcic P, Blagaic V, et al. Gastric pentadecapeptide BPC 157 counteracts morphine-induced analgesia in mice. J Physiol Pharmacol 2009; 60(Suppl. 7): 177-181.
  • 29- Sikiric P, Seiwerth S, Grabarevic Z, et al. Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci 1993; 53: PL291-PL296.
  • 31- Ilic S, Brcic I, Mester M, et al. Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. J Physiol Pharmacol 2009; 60(Suppl 7): 107-114.
  • 34- Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept 2010; 160: 33-41.
  • 36- Barisic I, Seiwerth S, Sikiric P, Sindic A. BPC 157 inhibits K+ conductance in WT HEK293 cells J Physiol Pharmacol 2009; 60(Suppl. 2): 10.
  • 38- Konturek SJ, Brzozowski T. Gastrointestinal and liver physiology. Preface. J Physiol Pharmacol 2008; 59(Suppl 2): 3-5.
  • 39- Brzozowski T, Konturek PC, Pajdo R, et al. Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipoxins. J Physiol Pharmacol 2008; 59(Suppl 2): 89-102.
  • 40- Konturek SJ, Brzozowski T, Konturek PC, et al. Brain-gut and appetite regulating hormones in the control of gastric secretion and mucosal protection. J Physiol Pharmacol 2008; 59(Suppl 2): 7-31.
  • 41- Sikiric P, Seiwerth S, Brcic L, et al. Revised Robert’s cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications. Curr Pharm Des 2010; in press.

BPC 157. ATTENUATED GASTRIC ULCERS, SEIZURES, BRAIN LESIONS, HEPATOMEGALY, FATTY LIVER

This trial shows the effectiveness of BPC157 on damages caused by insulin over dosage, which can be very useful for diabetics who inject themselves too much insulin… extracts:

 

OVER-DOSE INSULIN AND STABLE GASTRIC PENTADECAPEPTIDE BPC 157. ATTENUATED GASTRIC ULCERS, SEIZURES, BRAIN LESIONS,  HEPATOMEGALY, FATTY LIVER, BREAKDOWN OF LIVER GLYCOGEN, PROFOUND HYPOGLYCEMIA AND CALCIFICATION IN RATS

 

INTRODUCTION

The general significance of insulin induced ulcers remains not determined. We focused on hyperinsulinemia, deliberate injection of excessive insulin, and possibility that an anti-ulcer therapy with anti-ulcer peptide may be more successful counteracting therapy.

Insulin induced ulcers were long ago described, and related to gastric acid hypersecretion (1, 2).

Thus, to provide some novel intriguing insights, we focused on insulin induced gastric ulcers (1, 2) and then on other disturbances that may be concomitantly induced by insulin application (3-5).

 

We focused on a peptide therapy, using a small, orally active, anti-ulcer peptide (7-11) stable gastric pentadecapeptide BPC 157 (MW 1419) with very safe profile (LD1 could be not achieved, no side effects in clinical trials (12, 13) stable in human gastric juice (14), effective in trials for inflammatory bowel disease therapy (12, 13) and wound healing (15-18) also in diabetic rats (18, 19).

Importantly, pentadecapeptide BPC 157 was more active than recombinant human platelet-derived growth factor (PDGF-BB), stimulating both expression of early growth response 1 (egr-1) gene and its repressor nerve growth factor 1- A binding protein-2 (NAB2) (18).

Thereby, it may be important for cytokine induction, growth factor generation, early extracellular matrix (collagen) formation (18), but also for gluconeogenesis regulation (20).

Finally, alloxan-gastric ulcers in rats and mice may be inhibited by stable gastric pentadecapeptide BPC 157 (21).

 

DISCUSSION

Thus, when given to insulin-rats, BPC 157 would be confronted with the all processes simultaneously occurring that eventually lead to stomach ulcer (1, 2), hypoglycemia and all mentioned disturbances and death in insulin over-dose-rats (3-5). However, we shown that pentadecapeptide BPC 157, as an antiulcer peptide (7-11), may besides stomach ulcer consistently counteract all insulin disturbances and fatal outcome. This may also indicate that these disturbances are also interconnected throughout BPC 157 background. Moreover, considering the used insulin (250 IU/kg i.p.) /BPC 157 (10 µg, 10 ng/kg i.p. or i.g.) ratio (7, 8), it may be reasonably to assume that these therapy effects may indicate a likely role of BPC 157 in insulin controlling and influence on one or more causative process(es).

 

In conclusion, these findings demonstrate that when one application of very high dose of insulin may induce together stomach ulcer, seizures, severely damaged neurons in cerebral cortex and hippocampus, hepatomegaly, fatty liver, breakdown of liver glycogen with profound hypoglycemia, along with calcium deposition, and finally fatal outcome in rats, all damages were markedly attenuated when BPC 157 was applied.

The same effectiveness when given intraperitoneally or intragastrically (i.e., stable in human gastric juice (14)) may be suggestive that BPC 157 may have also an incretin role in controlling insulin effects (7, 8, 11).

Intriguingly, further studies may show whether standard anti-ulcer agents that prevent insulin-stomach ulcer (1, 2) may also have a broader beneficial effect on other disturbances presented in insulin-rats.

Previously, BPC 157 was shown to counteract toxic effects of other insulin preparations (43).

 

Source for this article: http://www.jpp.krakow.pl/journal/archive/12_09_s7/articles/13_article.html

 

Useful References:

  • 7. Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol (Paris) 1993; 87: 313-327.
  • 8. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology 2006; 14: 214-221.
  • 9. Sikiric P, Siwerth S, Grabarevic Z, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesion induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promoters and gut peptides. Life Sci 1994; 54: 63-68.
  • 10. Sikiric P, Seiwerth, S, Grabarevic Z, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol 1997; 332: 23-33.
  • 11. Sikiric P, Seiwerth S, Grabarevic Z, et al. Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Dig Dis Sci 1996; 41: 1518-1526.
  • 12. Veljaca M, Pavic-Sladoljev D, Mildner B, et al. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut 2003; 51: A309.
  • 13. Ruenzi M, Stolte M, Veljaca M, Oreskovic K, Peterson J. A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology 2005; 128: A584.
  • 14. Veljaca M, Chan K, Guglietta A. Digestion of h-EGF, h-TGF alpha and BPC 157 in human gastric juice. Gastroenterology 1995; 108: 761.
  • 15. Sikiric P, Seiwerth S, Mise S, et al. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns 2003; 29: 323-334.
  • 16. Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today 2008; 38: 716-725.
  • 17. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J Orthop Res 2006; 24: 1109-1117.
  • 18. Tkalcevic VI, Cuzic S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol 2007; 570(1-3): 212-221.
  • 20. Berasi SP, Huard C, Li D, et al. Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase. J Biol Chem 2006; 281: 27167-27177.
  • 21. Petek M, Sikiric P, Anic T, et al. Pentadecapeptide BPC 157 attenuates gatric lesions induced by alloxan in rats and mice. J Physiol (Paris) 1999; 93: 501-504.
  • 43. Ilic S, Mester M, Filipovic M, et al. Stable gastric pentadecapeptide BPC 157 and insulin induced gastric lesions in rats. J Physiol Pharmacol 2009; 60(Suppl 2): 40.

BPC 157 as an effective therapy for muscle crush injury

This trial shows that BPC157 accelerates muscle healing and to restore full muscle function!

 

Surgery-Today-JournalSurgery Today Journal
August 2008, Volume 38, Issue 8, pp 716-725

Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat
Purpose
Stable gastric pentadecapeptide BPC 157 accelerates the healing of a transected Achilles tendon and a transected quadriceps muscle. It may also be of clinical relevance as a systemic and local peptide treatment for crush injury of a major muscle, such as gastrocnemius muscle complex. BPC 157 is effective without a carrier, and it is presently undergoing trials for inflammatory bowel disease, and no toxicity has so far been reported.

Methods
In crushed rats (force delivered 0.727 Ns/cm2), BPC 157 was applied either intraperitoneally or locally, as a thin cream layer, immediately after injury (sacrifice at 2 h), and once a day for 14 days.

Results
BPC 157 improved muscle healing, macroscopically (less hematoma and edema, no post-injury leg contracture), microscopically, functionally, and also based on enzyme activity (creatine kinase, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase).

 

Conclusion
BPC 157, at all investigated intervals, given locally or intraperitoneally, accelerated post-injury muscle healing and also helped to restore the full function.

 

Key words
BPC 157 Crush injury Peptide therapy Muscle regeneration Rat

Source for this article: http://link.springer.com/article/10.1007%2Fs00595-007-3706-2

 

Useful References:

  • 1. Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, Rotkvic I, et al. A new gastric peptide BPC. An overview of stomach — organoprotection hypothesis and beneficial effect of BPC. J Physiol (Paris) 1993;87:313–327.
  • 2. Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology 2006;14:214–221.
  • 4. Jelovac N, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, et al. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. Eur J Pharmacol 1999;379:19–31.
  • 5. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Dig Dis Sci 1996;41:1604–1614.
  • 6. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol 1997;332:23–33.
  • 7. Sikiric P, Seiwerth S, Mise S, Staresinic M, Bedekovic V, Zarkovic N, et al. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns 2003;29:323–334.
  • 8. Veljaca M, Chan K, Guglietta A. Digestion of h-EGF, h-TGF alpha, and BPC-15 in human gastric juice. Gastroenterology 1995;108:761.
  • 12. Staresinic M, Petrovic I, Novinscak T, Jukic I, Pevec D, Suknaic S, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res 2006;24:1109–1117.
  • 14. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res 2006;24:982–989.
  • 15. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003;21:976–983.
  • 16. Sebecic B, Nikolic V, Sikiric P, Seiwerth S, Sosa T, Patrlj L, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone 1999;24:195–202.
  • 17. Bilic M, Bumber Z, Blagaic AB, Batelja L, Seiwerth S, Sikiric P. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice. Burns 2005;31:310–315.
  • 18. ikus D, Sikiric P, Seiwerth S, Petricevic A, Aralica G, Druzijanic N, et al. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns 2001;127:817–827
  • 19. Seiwerth S, Sikiric P, Grabarevic Z, Zoricic I, Hanzevacki M, Ljubanovic D, et al. BPC 157’s effect on healing. J Physiol (Paris) 1997;91:173–178.
  • 21. Xue XC, Wu YJ, Gao MT. Study of the protective effects of pentadecapeptide BPC 157 on wounds in small type pigs. Chin New Drugs J 2004;12:602–604.
  • 23. Gjurasin M, Miklic P, Buljat G, Perovic D, Jukic I, Sikiric P, et al. Selective healing effect of the gastric pentadecapeptide BPC 157 on injured part of the nerve in subtotal sciatic nerve transection. Dig Dis Sci 2003;48:1878.
  • 24. Vuksic T, Zoricic I, Brcic L, Sever M, Klicek R, Radic B, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, Pliva, Croatia) heals ileoileal-anastomosis in rat. Surg Today 2007;37:768–777.
  • 34. Lovric-Bencic M, Sikiric P, Hanzevacki JS, Seiwerth S, Rogic D, Kusec V, et al. Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC 157 in rat and mouse. J Pharmacol Sci 2004;95:19–26.
  • 35. Prkacin I, Separovic J, Aralica G, Perovic D, Gjurasin M, Lovric-Bencic M, et al. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol (Paris) 2001;95:315–324.
  • 37. Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, et al. The effect of pentadecapeptide BPC 157, H2 blockers and sucralfate on new vessels and new granulation tissue formation. J Physiol (Paris) 1999;93:479–485.
  • 38. Veljaca M, Lesch CA, Sanchez B, Low J, Guglietta A. Protection of BPC-15 on TNBS-induced colitis in rats: possible mechanisms of action. Gastroenterology 1995;108:936.
  • 39. Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther 1994;272:417–422.

BPC 157 in trials for inflammatory bowel disease

This trial shows the important effectiveness of BPC157 against various lesions in gastrointestinal tract!

 

Inflammopharmacology-JournalInflammopharmacology Journal

Volume 14, Issue 5-6, December 2006

Abstract.
Gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419, safe in clinical trials for inflammatory bowel disease (PL 10, PLD 116, PLD 14736, Pliva, Croatia)) has a particular cytoprotective/adaptive cytoprotective activity.

The cytoprotective/adaptive cytoprotection researches largely neglect that stomach distension could per se jeopardize the mucosal integrity, with constantly stretched mucosa and blood vessels, and sphincters more prone for reflux induction. After absolute alcohol instillation in fully distended rat stomach, gastric, esophageal and duodenal lesions occur. Throughout next 3 min, left gastric artery blood vessels clearly disappear at the serosal site, indicative for loss of vessels both integrity and function.

Contrary, constant vessels presentation could predict the beneficial effect of applied agent. After pentadecapeptide BPC 157 instillation into the stomach the vessels presentation remains constant, and lesions of stomach, esophagus, and duodenum are inhibited. Standards (atropine, ranitidine, omeprazole) could only slightly improve the vessels presentation compared to control values, and they have only a partial effect on the lesions.

In this review we emphasize BPC 157 unusual stability, and some of its important effects: effectiveness against various lesions in gastrointestinal tract, on nitric oxide (NO)-system, and NO-agents effects, on somatosensory neurons, salivary glands function, recovery of AMP-ADP-ATP system, endothelium protection, effect on endothelin, and on angiogenesis promotion.

It also antagonizes other alcohol effects, including acute and chronic intoxication.

Given peripherally, it counteracts the consequence of central dopamine system disturbances (receptor blockade), and induces serotonin release in substantia nigra.

Therapeutic potential of BPC 157 as a cytoprotective agent is also seen in its capability to heal various wounds.

Given directly into the stomach, BPC 157 instantly recovers disturbed lower esophageal and pyloric sphincter pressure in rats after 12–20 months of untreated esophagitis.

All these could be suggestive for its role as a natural protectant in gastric juice with particular function throughout stomach distension.
Key words.
Stable Gastric Pentadecapeptide BPC 157-PL 10 PLD 116 PLD 14736 Cytoprotective agent Healing

 

Source for this article: http://link.springer.com/article/10.1007%2Fs10787-006-1531-7

 

Protective effects of pentadecapeptide BPC 157 on gastric ulcer

This trial shows the power of BPC157 to repair ulcer gastric damages!

 

World Journal of Gastroenterol 

2004 April 1

Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats.
AIM:
To investigate the protective effects of gastric pentadecapeptide BPC 157 on acute and chronic gastric ulcers in rats and to compare the results in therapy of human gastric ulcers by different administration methods.

METHODS:
Gastric pentadecapeptide BPC 157 was administered (initial single or continuous administration) into rats either intragastrically or intramuscularly before (induced acute gastric ulcer) or after (induced chronic gastric ulcer) the applications of inducing agents, and each animal was sacrificed to observe the protective effects of BPC 157 on gastric ulcers.

RESULTS:
Both intramuscular (im) and intragastric (ig) administration of BPC 157 could apparently reduce the ulcer area and accelerate the healing of induced ulcer in different models and the effect of im administered BPC 157 was better than that of ig. The rats treated with higher dosages (400 ng/kg, 800 ng/kg) of BPC 157 (im and ig) showed significantly less lesion (P<0.01 vs excipient or saline control), the inhibition ratio of ulcer formation varied between 45.7% and 65.6%, from all measurements except 400 ng/kg BPC 157 in pylorus ligation induced model (P<0.05), in which the inhibition rate was 54.2%. When im administered (800 ng/kg BPC 157) in three models, the inhibition ratio of ulcer formation was 65.5%, 65.6% and 59.9%, respectively, which was better than that of famotidine (its inhibition rate was 60.8%, 57.2% and 34.3%, respectively). Continuous application of BPC 157 (in chronic acetate induced gastric ulcer) could accelerate rebuilding of glandular epithelium and formation of granulation tissue (P<0.05 at 200 ng/kg and P<0.01 at 400 ng/kg and 800 ng/kg vs excipient or saline control).

CONCLUSION:
Both im and ig administered gastric pentadecapeptide BPC 157 can apparently ameliorate acute gastric ulcer in rats and antagonize the protracted effect of acetate challenge on chronic ulcer.

The effect of im administration of BPC 157 is better than that of ig, and the effective dosage of the former is lower than that of the latter.

 

Source of this article: http://www.wjgnet.com/1007-9327/10/1032.asp

or http://www.ncbi.nlm.nih.gov/pubmed/15052688?dopt=Abstract

 

Useful references:

  • 1. Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, Rotkvic I, Jagic V, Turkovic B, Mildner B, Duvnjak M. The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures. Physiol Hung 1992; 80: 89-98
  • 2. Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, Rotkvic I, Turkovic B, Jagic V, Mildner B, Duvnjak M. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 1993; 87: 313-327
  • 3. Prkacin I, Separovic J, Aralicia G, Perovic D, Gjurasin M, Lovric-Bencic M, Stancic-Rokotov D, Staresinic M, Anic T, Mikus D, Sikiric P, Seiwerth S, Mise S, Rotkvic I, Jagic V, Rucman R, Petek M, Turkovic B, Marovic A, Sebecic B, Boban-Blagaic A, Kokic N. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol Paris 2001; 95: 315-324
  • 4. Stancic-Rokotov D, Slobodnjak Z, Aralica J, Aralica G, Perovic D, Staresinic M, Gjurasin M, Anic T, Zoricic I, Buljat G, Prkacin I, Sikiric P, Seiwerth S, Rucman R, Petek M, Turkovic B, Kokic N, Jagic V, Boban-Blagaic A. Lung lesions and anti-ulcer agents beneficial effect: anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rats. J Physiol Paris 2001; 95: 303-308
  • 7. Sikiric P, Seiwerth S, Grabarevic Z, Balen I, Aralica G, Gjurasin M, Komericki L, Perovic D, Ziger T, Anic T, Prkacin I,
    Separovic J, Stancic-Rokotov D, Lovric-Bencic M, Mikus D, Staresinic M, Aralica J, DiBiaggio N, Simec Z, Turkovic B,
    Rotkvic I, Mise S, Rucman R, Petek M, Sebecic B, Ivasovic Z, Boban-Blagaic A, Sjekavica I. Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone. J Physiol Paris 2001; 95: 261-270
  • 8. Mikus D, Sikiric P, Seiwerth S, Petricevic A, Aralica G, Druzijancic N, Rucman R, Petek M, Pigac B, Perovic D, Kolombo M, Kokic N, Mikus S, Duplancic B, Fattorini I, Turkovic B, Rotkvic I, Mise S, Prkacin I, Konjevoda P, Stambuk N, Anic T. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns
    2001; 27: 817-827
  • 9. Prkacin I, Aralica G, Perovic D, Separovic J, Gjurasin M, Lovric-Bencic M, Stancic-Rokotov D, Ziger T, Anic T, Sikiric P,
    Seiwerth S, Staresinic M, Mise S, Rotkvic I, Jagic V, Rucman R, Petek M, Turkovic B, Marovic A, Sjekavica I, Sebecic B,
    Boban-Blagaic A, Ivasovic Z. Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent,
    attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J Physiol Paris 2001;95:295-301
  • 10. Bilic I, Zoricic I, Anic T, Separovic J, Stancic-Rokotov D, Mikus D, Buljat G, Ivankovic D, Aralica G, Prkacin I, Perovic D,
    Mise S, Rotkvic I, Petek M, Rucman R, Seiwerth S, Sikiric P. Haloperidol-stomach lesions attenuation by
    pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine,
    cimetidine and misoprostol in mice. Life Sci 2001; 68: 1905-1912
  • 11. Sikiric P, Marovic A, Matoz W, Anic T, Buljat G, Mikus D, Stancic-Rokotov D, Separovic J, Seiwerth S, Grabarevic Z,
    Rucman R, Petek M, Ziger T, Sebecic B, Zoricic I, Turkovic B, Aralica G, Perovic D, Duplancic B, Lovric-Bencic M,
    Rotkvic I, Mise S, Jagic V, Hahn V. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson’s disease
    models in mice and gastric lesions induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydrophyridine. J Physiol Paris
    1999; 93: 505-512
  • 12. Petek M, Sikiric P, Anic T, Buljat G, Separovic J, Stancic-Rokotov D, Seiwerth S, Grabarevic Z, Rucman R, Mikus D, Zoricic
    I, Prkacin I, Sebecic B, Ziger T, Coric V, Turkovic B, Aralica G, Rotkvic I, Mise S, Hahn V. Pentadecapeptide BPC 157
    attenuates gastric lesions induced by alloxan in rats and mice. J Physiol Paris 1999; 93: 501-504
  • 13. Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, Rotkvic I, Jagic V, Duvnjak M, Mise S. The beneficial
    effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress,
    cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut
    peptides. Life Sci 1994; 54: PL63-68
  • 14. Sikiric P, Jelovac N, Jelovac-Gjeldum A, Dodig G, Staresinic M, Anic T, Zoricic I, Ferovic D, Aralica G, Buljat G, Prkacin I,
    Lovric-Bencic M, Separovic J, Seiwerth S, Rucman R, Petek M, Turkovic B, Ziger T. Anxiolytic effect of BPC-157, a gastric
    pentadecapeptide: shock probe/burying test and light/dark test. Acta Pharmacol Sin 2001; 22: 225-230
  • 15. Sikiric P, Separovic J, Buljat G, Anic T, Stancic-Rokotov D, Mikus D, Marovic A, Prkacin I, Duplancic B, Zoricic I, Aralica G,
    Lovric-Bencic M, Ziger T, Perovic D, Rotkvic I, Mise S, Hanzevacki M, Hahn V, Seiwerth S, Turkovic B, Grabarevic Z,
    Petek M, Rucman R. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt’s test and chronic
    unpredictable stress in rats. A comparison with antidepressants. J Physiol Paris 2000; 94: 99-104
  • 16. Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, Grabarevic Z, Stancic-Rokotov D, Pigac B, Hanzevacki M,
    Marovic A, Rucman R, Petek M, Zoricic I, Ziger T, Aralica G, Konjevoda P, Prkacin I, Gjurasin M, Miklic P, Artukovic B,
    Tisljar M, Bratulic M, Mise S, Rotkvic I. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate
    on new vessels and new granulation tissue formation. J Physiol Paris 1999; 93: 479-485
  • 17. Sebecic B, Nikolic V, Sikiric P, Seiwerth S, Sosa T, Patrlj L, Grabarevic Z, Rucman R, Petek M, Konjevoda P, Jadrijevic S,
    Perovic D, Slaj M. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in
    rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone 1999; 24: 195-202
  • 18. Jelovac N, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, Seiwerth S, Mise S, Turkovic B, Dodig G, Miklic P, Buljat G,
    Prkacin I. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and
    gastric ulcers in mice and rats. Eur J Pharmacol 1999; 379: 19-31
  • 19. Sikiric P, Seiwerth S, Deskovic S, Grabarevic Z, Marovic A, Rucman R, Petek M, Konjevoda P, Jadrijevic S, Sosa T,
    Perovic D, Aralica G, Turkovic B. New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin. Eur J Pharmacol 1999; 364: 23-31
  • 20. Sikiric P, Jelovac N, Jelovac-Gjeldum A, Dodig G, Staresinic M, Anic T, Zoricic I, Rak D, Perovic D, Aralica G, Buljat G,
    Prkacin I, Lovric-Bencic M, Separovic J, Seiwerth S, Rucman R, Petek M, Turkovic B, Ziger T, Boban-Blagaic A,
    Bedekovic V, Tonkic A, Babic S. Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior
    disturbances. Acta Pharmacol Sin 2002; 23: 412-422
  • 21. Sikiric P, Jadrijevic S, Seiwerth S, Sosa T, Deskovic S, Perovic D, Aralica G, Grabarevic Z, Rucman R, Petek M, Jagic V,
    Turkovic B, Ziger T, Rotkvic I, Mise S, Zoricic I, Sebecic B, Patrlj L, Kocman B, Sarlija M, Mikus D, Separovic J,
    Hanzevacki M, Gjurasin M, Miklic P. Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or
    cholestyramine application in reflux oesophagitis in rats. J Physiol Paris 1999; 93: 467-477
  • 22. Sikiric P, Separovic J, Buljat G, Anic T, Stancic-Rokotov D, Mikus D, Duplancic B, Marovic A, Zoricic I, Prkacin I,
    Lovric-Bencic M, Aralica G, Ziger T, Perovic D, Jelovac N, Dodig G, Rotkvic I, Mise S, Seiwerth S, Turkovic B,
    Grabarevic Z, Petek M, Rucman R. Gastric mucosal lesions induced by complete dopamine system failure in rats. The
    effects of dopamine agents, ranitidine, atropine, omeprazole and pentadecapeptide BPC 157. J Physiol Paris
    2000; 94: 105-110
  • 23. Jelovac N, Sikiric P, Rucman R, Petek M, Perovic D, Marovic A, Anic T, Seiwerth S, Mise S, Pigac B, Duplancie B,
    Turkovic B, Dodig G, Prkacin I, Stancic-Rokotov D, Zoricic I, Aralica G, Sebecic B, Ziger T, Slobodnjak Z. The effect of a
    novel pentadecapeptide BPC 157 on development of tolerance and physical dependence following repeated
    administration of diazepam. Chin J Physiol 1999; 42: 171-179

Pharmacological properties of peptide BPC 157

This trial demonstrates the multi-capabilities of BPC157 to repair and protect numerous organs in our body.

 

Inflammopharmacology-Journal

Inflammo Pharmacology Journal
March 1999, Volume 7, Issue 1, pp 1-14

Abstract

The reported beneficial effects of the gastric mucosal derived pentadecapeptide BPC 157 (Gly Glu Pro Pro Pro Gly Lys Pro Ala Asp Asp Ala Gly Leu Val, M.W. 1419) on different organ lesions are reviewed.

Apart from the effects on various gastrointestinal lesions, the potentially beneficial effect on pancreas, liver injuries, endothelium and heart damage, i.e. dysrhythmias following reoxygenation, and blood pressure, along with effect on experimental acute/chronic inflammation, wound and fracture (pseudoarthrosis) healing are described.

It appears that these beneficial effects all together provide a particular network reflecting activity of a special peptidergic defence system. In support of this concept, it appears that there are interactions of this pentadecapeptide with many important systems (namely, dopamine-, NO-, prostaglandin-, somatosensory neurone-systems), that could provide a basis for the observed protective effects. Moreover, since disturbance of these systems’ functions (i.e. dopamine-, NO-, somatosensory neuronal-system) which manifest either over-activity or as inhibition, may contribute to the multiple lesions in different organs.

The reported evidence that this pentadecapeptide is able to counteract both their over-action, and their inhibition, may suggest this pentadecapeptide as a new, but most probably essential physiological defence system and that should be further investigated.

 

Key words:
BPC 157 (PL-10) gastrointestinal lesions acute pancreatitis liver lesions inflammation and pain heart blood pressure behaviour physiological defence system

Source for this article: http://link.springer.com/article/10.1007%2Fs10787-999-0022-z

 

Useful Cited References:

  • 2. Sikiric, P., Petek, M., Rucman, R., etal. (1993). A new gastric juice peptide BPC — an overview of stomach/stress/organoprotection hypothesis and BPC beneficial effects, J. Physiol. (Paris) 87,313–327.
  • 3. Sikiric, P., Gyires, K., Seiwerth, S., et al. (1993). The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity, Inflammopharmacology 2, 121–127.
  • 4. Sikiric, P., Banic, M., Brkic, T., et al. (1993). Effects of a novel pentadecapeptide BPC 157 and methylprednisolone in a murine model of inflammatory bowel disease, Gastroenterology 104, 782.
  • 5. Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. (1993). Hepatoprotective effect of BPC 157, a 15-aminoacid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCI4 application. A comparative study with dopamine agonists and somatostatin, Life Sci. 53, PL291-PL296.
  • 6. Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. (1994). The beneficial effect of BPC 157, a 15 aminoacid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides, Life Sci. 54, PL63-PL68.
  • 7. Sikiric, P., Rotkvic, I., Mise, S. et al. (1995). Dopamine agents efficacy in peptic ulcer healing and relapse prevention — a further indication for importance of stomach dopamine in the stress organoprotection concept, in: Neuroendocrinology of Gastrointestinal Ulceration: Hans Selye Symposia on Neuroendocrinology and Stress, Szabo, S., Taché, Y. and Glavin, G. (Eds), Vol. 2, pp. 221–230. Plenum, New York.
  • 8. Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. (1996). Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats, Digestive Disease Sci. 41, 1518–1526.
  • 9. Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. (1996). The beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin and capsaicin neurotoxicity, Digestive Disease Sci. 41, 1604–1614.
  • 10. Sikiric, P., Mazul, B., Seiwerth, S., et al. (1997). Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress, Digestive Disease Sci. 42, 661–671.
  • 11. Sikiric, P., Mikus, D., Seiwerth, S., et al. (1997). Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine and atropine effect in cysteamine lesions in totally gastrectomized rats. A model study for cytoprotective studies, Digestive Disease Sci. 42, 1029–1037.
  • 12. Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. (1997). The influence of a novel pentadecapeptide BPC 157 on NG-nitro-L~arginine methylester and L-arginine effect on stomach mucosal integrity and blood pressure, European J. Pharmacol. 332, 23–33.
  • 13. Grabarevic, Z., Tisljar, M., Artukovic, B., et al. (1997). The influence of BPC 157 on nitric oxide agonists and antagonist induced lesions in broiler chicks, J. Physiol. (Paris) 91, 139–150.
  • 15. Jelovac, N., Sikiric, P., Rucman, R., et al. (1998). A novel pentadecapeptide BPC 157 blocks the stereotypy produced acutely by amphetamine and the developement of haloperidol-induced supersensitivity to amphetamine, Biol. Psych. 43, 511–519.CrossRef
  • 16. Konjevoda, P., Nasic, M., Curkovic, T, Sikiric, P., Seiwerth, S. and Stambuk, N. (1998). Effects of BPC 157 on the healing of corneal lesions, in: Uveitis Today, Ohno, S., Aoki, K., Usui, M. and Uchio, E. (Eds), pp. 311–314. Elsevier, Amsterdam.
  • 17. Kalogjera, L., Ries, N., Baudoin, T., Ferencic, Z., Protic, R. and Pegan, B. (1997). Dose dependent protective effect of BPC 157 in capasaicin induced rhinitis in rats, European Arch. Otorhinolaryngol. 254, S9-S11.
  • 18. Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. (1997). Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agents-induced gastrointestinal lesions and adjuvant arthritis in rats, J. Physiol. (Paris) 91, 113–122.
  • 20. Sebecic, B., Nikolic, V., Sikiric, P. et al. (1999). Osteogenic effect of a gastric pentadecapeptide BPC 157, on the healing of segmental bone defect in rabbits. A comparison with bone marrow and autologous cortical bone implantation, Bone 24, 195–202.
  • 21. Zoricic, I., Sikiric, P., Seiwerth, S., et al. (1997). Pentadecapeptide BPC 157 beneficially influences the healing of colon-colon anastomoses in rats, in: Cell Injury and Protection in the Gastrointestinal Tract. From basic sciences to clinical perspectives 1996, Mozsik, Gy., Nagy, L., Par, A. and Rainsford, K. D. (Eds), pp. 249–258. Kluwer Academic Publishers, Dordrecht.
  • 22. Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. (1997). The effect of pentadecapeptide BPC 157, H2 blockers and sucralfate on new vessels and new granulation tissue formation, Gastroenterology 112,291.
  • 23. Sikiric, P., Jadrijevic, S., Seiwerth, S., et al. (1997). Pentadecapeptide BPC 157 reduces esophagojejunal anastomosis-esophageal ulceration in rats, Gastroenterology 112, 219.
  • 25. Bodis, B., Karadi, O., Nagy, L., et al. (1997). Evidence for direct cellular protective effect of PL-10 substances (synthesized parts of body protection compound BPC) and their specificity to gastric mucosal cells, Life Sci. 61, PL 243-PL 248.
  • 26. Veljaca, M., Pllana, R., Lesch, C. A., Sanchez, B., Chan, K. and Guglietta, A. (1994). Protective effect of BPC 157 on a rat model of colitis, Gastroenterology 106, 789.
  • 27. Veljaca, M., Lech, C. A., Pllana, R., Sanchez, B., Chan, K. and Guglietta, A. (1994). BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats, J. Pharmacol. Exp. Ther. 272,417–422.
  • 28. Veljaca, M, Chan, K. and Guglietta, A. (1995). Digestion of h-EGF, h-TGF α, and BPC 15 in human gastric juice, Gastroenterology 108, 761.
  • 29. Veljaca, M., Lesch, C. A., Sanchez, B., Low, J. and Guglietta, A. (1995). Protection of BPC-15 on TNBS-induced colitis in rats: possible mechanisms of action, Gastroenterology 108, 936.
  • 30. Bosnjak, Z. J., Graf, B. M. and Sikiric, P. (1994). Protective effects of newly isolated gastric peptide following hypoxic and reoxygenation injury in the isolated guinea pig heart, FASEB J. 8, A 129.
  • 31. Sandor, Z., Vincze, A. and Szabo, S. (1996). The protective effect of a recently isolated gastric peptide in acute and chronic gastroduodenal injury, FASEB J. 10, 171.
  • 32. Sandor, Z., Vincze, A., Jadus, M. R., et al. (1997). The protective effect of newly isolated peptide PL-10 in the iodoacetamide colitis model in rats, Gastroenterology 112, 400.
  • 33. Paré, W. and Kluczynski, J. M. (1994). The effect of new gastric juice peptide BPC on classic stress triad in stress procedure, Exp. Clin. Gastroenterol. 2, 234–236.
  • 34. Erceg, D., Simicevic, V. N., Kolega, M. and Dohoczky, C. (1997). Some aspects of PL-10.1.AK- 15 on the gastrointestinal tract, J. Physiol. (Paris) 91, 179–181.

BPC 157 Interactions in Mucosal Protection in Stress

This trial studies several mechanisms of action for BPC157.

 

Digestive-Diseases-and-Sciences-JournalDigestive Diseases and Sciences Journal
March 1997, Volume 42, Issue 3, pp 661-671

Pentadecapeptide BPC 157 Interactions with Adrenergic and Dopaminergic Systems in Mucosal Protection in Stress

 

Abstract
Since superior protection against different gastrointestinal and liver lesions and anti inflammatory and analgesic activities were noted for pentadecapeptide BPC (an essential fragment of an organoprotective gastric juice protein named BPC), the beneficial mechanism of BPC 157 and its likely interactions with other systems were studied.

Hence its beneficial effects would be abolished by adrenal gland medullectomy, the influence of different agents affectingα, β, and dopamine receptors on BPC 157 gastroprotection in 48 h restraint stress was further investigated. Animals were pretreated (1 hr before stress) with saline (controls) or BPC 157 (dissolved in saline) (10 μg or 10 ng/kg body wt intra peritoneally or intra gastrically) applied either alone to establish basal conditions or, when manipulating the adrenergic or dopaminergic system, a simultaneous administration was carried out with various agents with specific effects on adrenergic or dopaminergic receptors[given in milligrams per kilogram intraperitoneally except for atenolol, which was given subcutaneously] phentolamine (10.0), prazosin (0.5),yohimbine (5.0), clonidine (0.1) (α-adrenergicdomain), propranolol (1.0), atenolol (20.0)(β-adrenergic domain), domperidone (5.0), and haloperidol(5.0) (peripheral/central dopamine system).

Alternatively, agents stimulating adrenergic ordopaminergic systemsadrenaline (5.0) or bromocriptine(10.0)-were applied. A strong protection, noted following in tragastric or intraperitoneal administration of BPC157, was fully abolished by co administration of phentolamine, clonidine, and haloperidol, andconsistently not affected by prazosin, yohimbine, ordomperidone.

Atenolol abolished only intraperitoneal BPC 157 protection, whereas propranolol affected specifically intragastric BPC 157 protection.Interestingly, the severe course of lesion developmentobtained in basal conditions, unlike BPC 157gastroprotection, was not influenced by the applicationof these agents. In other experiments, when adrenaline and bromocriptine were given simultaneously, a strong reduction of lesion development was noted.

However, when applied separately, only adrenaline, not bromocriptine, has aprotective effect. Thus, a complex protectiveinteraction with both α-adrenergic (e.g.,catecholamine release) and dopaminergic (central)systems could be suggested for both intragastric and intraperitoneal BPC 157 administration.

The involvement of β-receptor stimulation in BPC 157 gastroprotection appears to be related to the route of BPC 157 administration.The demonstration that a combined stimulation of adrenergic and dopaminergic systems by simultaneous prophylactic application of adrenaline(α- and β-receptor stimulant) and bromocriptine (dopamine receptor agonist) may significantly reduce restraint stress lesions development provides insight for further research on the beneficial mechanism of BPC 157.

 

Keywords

PENTADECAPEPTIDE BPC 157 PEPTIDE BPC GASTROPROTECTION ADRENERGIC DOPAMINERGIC SYSTEMS STRESS INTERACTION

Source for this article: http://link.springer.com/article/10.1023%2FA%3A1018880000644

Beneficial effect of BPC 157 on gastric lesions

This trial demonstrates the synergistic activity of BPC157 with certain neurons!

 

Digestive-Diseases-and-Sciences-JournalDigestive Diseases and Sciences Journal

August 1996, Volume 41, Issue 8, pp 1604-1614

Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity

 

Abstract
Very recently, the integrity of capsaicin somato sensory neurons and their protection were suggested to be related to the activity in nociception of a newly discovered 15-amino acid peptide, BPC 157, shown to have strong beneficial effect on intestinal and liver lesions.

Therefore, from this viewpoint, we have studied the gastroprotective effect of the pentadecapeptide BPC 157, on gastric lesions produced in rats by 96% ethanol, restraint stress, and indomethacin.

The possible involvement of sensory neurons in the salutary actions of BPC 157 (10µg/kg, 10 ng/kg intraperitoneally) was studied with capsaicin, which has differential effects on sensory neurons: a high dose in adult (125 mg/kg subcutaneously, 3 months old) or administration (50 mg/kg subcutaneously) to neonatal animals (age of the 7 days) destroys sensory fibers, whereas a low dose (500µg/kg intraperitoneally) activates neurotransmitter release and protective effects on the mucosa.

In the absence of capsaicin, BPC 157 protected gastric mucosa against ethanol, restraint, and indomethacin application. In the presence of neurotoxic doses of capsaicin, the negative influence of capsaicin on restraint, ethanol, or indomethacin lesions consistently affected salutary activity of BPC 157.

However, BPC 157 protection was still evident in the capsaicin-treated rats (either treated as adults or as newborns) in all of these assays. Interestingly, after neonatal capsaicin treatment, a complete abolition of BPC gastroprotection was noted if BPC 157 was applied as a single nanogram-regimen, but the mucosal protection was fully reversed when the same dose was used daily. In line with the excitatory dose of capsaicin the beneficial effectiveness of BPC 157 appears to be increased as well.

Taken together, these data provide evidence for complex synergistic interaction between the beneficial effectiveness of BPC 157 and peptidergic sensory afferent neuron activity.

 

Key words
pentadecapeptide BPC 157 organoprotective peptide gastric lesions capsaicin neurotoxicity rats gastroprotection neuroprotection

 

Source for this article: http://link.springer.com/article/10.1007%2FBF02087908

 

Useful Cited References:

  • 12. Sikiric P, Petek M, Rucman R, Rotkvic I, Seiwerth S, Grabarevic Z, Jagic V, Turkovic B, Mildner B, Duvnjak M, Cviko A, Kolega M, Dodig M, Sallmani A, Djacic S, Lucinger D, Erceg D: The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures.In Cell Injury and Protection in the Gastrointestinal Tract: From Basic Sciences to Clinical Perspectives. Gy Mózsik, A Pár, G Csomós, M Kitajima, M Kondo, CJ Pfeiffer, KD Rainsford, P Sikiric, S Szabo (eds). Budapest, Akedémiai Kiadó, 1992, pp 89–98
  • 13. Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, Rotkvic I, Jagic V, Mildner B, Duvnjak M, Lang N: A new gastric juice peptide, BPC-an overview of stomach/stress/organoprotection hypothesis and BPC beneficial effects. J Physiol (Paris) 87:313–327, 1993
  • 14. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Rotkvic I, Turkovic B, Jagic V, Mildner B, Duvnjak M, Danilovic Z: Hepatoprotective effect of BPC 157, a 15-aminoacid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci 53:PL291-PL296, 1993
  • 15. Sikiric P, Gyires K, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Rotkvic I, Turkovic B, Udovicic I, Jagic V, Mildner B, Duvnjak M, Danilovic Z: The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity. Inflammopharmacology 2:121–127, 1993
  • 16. Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, Rotkvic I, Jagic V, Duvnjak M, Mise S, Djacic S, Separovic J, Veljaca M, Sallmani A, Banic M, Brkic T: The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duododenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promoters and gut peptides. Life Sci 54:PL63-PL68, 1994
  • 18. Mózsik Gy, Sikiric P, Petek M: Gastric mucosal preventing body protective compound (BPC) effect on the development of ethanol and HCl-induced gastric mucosal injury. Exp Clin Gastroenterol 1:87–90, 1991
  • 19. Paré W, Klucyznski JM: The effect of new gastric juice peptide BPC on classic stress triad in stress procedure. Exp Clin Gastroenterol 2:234–236, 1992
    20.
    Veljaca M, Pllana R, Lesch CA, Sanchez B, Chan K, Guglietta A: Protective effect of BPC 157 on a rat model of colitis. Gastroenterology 106:789, 1994
  • 21. Veljaca M, Lech CA, Pllana R, Sanchez B, Chan K, Guglietta A: BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther 272:417–422, 1994
  • 22. Veljaca M, Lesch CA, Sanchez B, Low J, Guglietta A: Protection of BPC-15 on TNBS-induced colitis in rats: possible mechanisms of action. Gastroenterology 108:936, 1995
  • 23. Veljaca M, Chan K, Guglietta A: Digestion of h-EGF, h-TGF alpha, and BPC-15 in human gastric juice. Gastroenterology 108:761, 1995
  • 48. Kalogjera L, Ries N, Baudoin T, Ferencic Z, Seiwerth S, Sikiric P: Dose dependent protective effect of BPC 157 in capasaicin induced rhinitis in rats. European Arch Otorhynolaringol 1996 (in press)